AstraZeneca : Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumours -April 05, 2024 at 08:38 pm EDT

Based on three Phase II trials of AstraZeneca and Daiichi Sankyo's Enhertu which showed clinically meaningful responses across a broad range of tumours



...

Related Keywords

Australia ,Singapore ,Texas ,United States ,Brazil ,Daiichi Sankyo ,Dave Fredrickson ,Ken Keller ,Daiichi Sankyo Enhertu ,Astrazeneca ,Daiichi Sankyo Inc ,University Of Texas Md Anderson Cancer Center ,Drug Administration ,Investigational Cancer Therapeutics ,Cancer Center ,Executive Vice President ,Oncology Business Unit ,Global Head ,Oncology Business ,Practice Guidelines ,Time Oncology Review ,Priority Review ,Breakthrough Therapy Designation ,Project Orbis ,